Nuo Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
Roth Capital Initiates Coverage On Nuo Therapeutics with Buy Rating, Announces Price Target of $3
Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew
Nuo Therapeutics Enters Into Exclusive Private Label Distribution Agreement With Global Medical Technology Company For The CENTRIO Platelet-Rich Plasma System
Nuo Therapeutics and PAM Health Partner to Advance Access to Regenerative Wound Healing Therapies
Audeo Oncology Files to Withdraw S-1 for IPO
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
